Autologous Hematopoietic Stem Cell Transplantation For Progressive Multiple Sclerosis: Report Of Efficacy And Safety At Three Yr Of Follow Up In 21 Patients

Xiu-Shi Ni,Jiang Ouyang,Wen-Hui Zhu,Chong Wang,Bing Chen

DOI: https://doi.org/10.1111/j.1399-0012.2006.00510.x

2006-01-01

Clinical Transplantation

Abstract:Objective: To observe the efficacy and toxicity of autologous hematopoietic stem cell transplantation (HSCT) in progressive multiple sclerosis (PMS).Methodology: Twenty-one patients with PMS were treated with autologous HSCT. Stem cells were mobilized with cyclophosphamide (CY) and granulocyte colony-stimulating factor. After conditioning regimen of CY and total body irradiation or BEAM, stem cells were reinfused. CD34(+) cell selection of the graft was performed and anti-thymocyte globulin was given for T-cell depletion. The probabilities of confirmed progression-free survival and disease activity-free survival were used to assess the efficacy and the adverse experiences were recorded to detect the toxicities.Results: The median follow-up time was 42 (6-65) months. The probabilities of confirmed progression-free survival and the disease activity-free survival were 75% and 33.3%, respectively. The principal adverse events included allergy, infection, elevation of liver enzymes, transient neurologic deterioration and depression. Two patients died of severe pneumonia and varicella-zoster virus hepatitis, at 4.5 and 15 months post-transplant, respectively.Conclusions: Autologous HSCT seems beneficial to PMS. However, more patients and longer follow up would be required to assess the risk/benefit ratio.